503B outsourcing facility software that clears an FDA inspection the first time.
V5 Ultimate is a single-platform QMS + MES + environmental-monitoring system for US 503B outsourcing facilities. Full cGMP under 21 CFR 210/211, USP <797>/<800> alignment, DQSA product reporting and adverse-event tracking — designed for the way FDA inspects compounders.
You need 503B software because 503A tools don't survive an FDA inspection.
Your compounding software was built for 503A pharmacies — no cGMP batch record
USP <797>/<800> environmental monitoring is on paper, not tied to batches
Six-monthly DQSA product reports rebuild from spreadsheets every cycle
Adverse-event reporting to FDA is manual — traceability back to the batch is fragile
Beyond-use dating relies on tribal knowledge, not documented stability studies
Recent FDA inspections cited data integrity — you can't prove ALCOA+ on lab results
503B controls, in one instance.
cGMP batch records
Recipe-driven electronic batch records under 21 CFR 211 — the standard 503A tools were never designed to meet.
USP <797>/<800> monitoring
Viable and non-viable environmental monitoring, gowning qualifications, media fills — bound to the batches produced in each period.
DQSA product reporting
Six-monthly product reports assembled automatically from batch records — quantity, strength, dosage form, product identifier.
Adverse-event & recall
Adverse-event capture, root-cause investigation and recall execution — traced to the affected batch and downstream customer.
Beyond-use dating (BUD)
BUD calculated from documented stability studies, not defaults — with re-testing schedules and expiry-driven quarantine.
Data integrity (ALCOA+)
Attributable, legible, contemporaneous, original, accurate — plus complete, consistent, enduring, available. Enforced at every entry.
What 503B readiness looks like in a real inspection.
- First cGMP batch signed within 30 days of go-live
- DQSA six-monthly report generated in an afternoon, not a week
- Environmental monitoring bound to batches — every deviation traceable to affected product
- Adverse-event investigation closes in days with linked batch, complainant and root cause
- Zero-finding FDA inspections on Part 11 and data-integrity questions
The regulations a 503B is inspected against.
21 CFR 210 / 211 cGMP
Full pharmaceutical cGMP — 503B is treated as a manufacturer, not a pharmacy.
USP <797> / <800>
Sterile compounding standards and handling of hazardous drugs — engineering controls, monitoring, gowning.
DQSA Section 503B
Registration, product reporting, adverse-event reporting and inspection under FDA authority.
503B software, answered.
Isn't a 503B basically a pharmacy?
Legally, no. Section 503B outsourcing facilities are regulated as manufacturers under DQSA and inspected against full 21 CFR 210/211 cGMP. Pharmacy software built for 503A retail compounding won't pass an FDA inspection.
Does V5 cover both sterile and non-sterile compounding?
Yes. Sterile 503B facilities layer USP <797> monitoring and Annex-1-style contamination controls; non-sterile compounding drops those modules but keeps the cGMP batch record and QMS.
Can V5 generate our six-monthly DQSA product report?
Yes. The report assembles from the batch records — product name, dosage form, strength, package description, quantity, product identifier — with a QA signature layer before submission.
How does V5 handle beyond-use dating (BUD)?
BUD is calculated from documented stability studies stored in V5, not from software defaults. Expiries drive quarantine, re-testing schedules and destruction workflows.
Is the platform validated for 503B?
Yes — GAMP 5 Cat 4 with IQ/OQ/PQ delivered at onboarding, deployable on single-tenant private cloud (Azure/AWS) for validated 503B customers.
See a 503B batch and DQSA report run end-to-end.
Free trial. Validation evidence for 503B included at onboarding.